GlaxoSmithKline (GSK) Reaches New 12-Month Low at $1,270.00
GlaxoSmithKline plc (LON:GSK)’s share price reached a new 52-week low on Wednesday . The stock traded as low as GBX 1,270 ($17.09) and last traded at GBX 1,278 ($17.20), with a volume of 7551539 shares. The stock had previously closed at GBX 1,278 ($17.20).
Several equities analysts have weighed in on the company. Bryan, Garnier & Co reissued a “neutral” rating and set a GBX 1,710 ($23.01) price target on shares of GlaxoSmithKline in a research report on Tuesday, September 19th. Investec downgraded GlaxoSmithKline to a “hold” rating and dropped their price target for the stock from GBX 1,800 ($24.23) to GBX 1,390 ($18.71) in a research report on Monday, November 6th. Bank of America set a GBX 1,450 ($19.52) price target on GlaxoSmithKline and gave the stock a “neutral” rating in a research report on Wednesday. Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline in a research report on Monday, October 23rd. Finally, Jefferies Group dropped their price target on GlaxoSmithKline from GBX 1,700 ($22.88) to GBX 1,540 ($20.73) and set a “buy” rating for the company in a research report on Tuesday, October 31st. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of GBX 1,577.14 ($21.23).
GlaxoSmithKline (LON:GSK) last issued its quarterly earnings data on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) EPS for the quarter, topping the Zacks’ consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). The company had revenue of GBX 784.30 billion for the quarter. GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%.
The business also recently disclosed a dividend, which will be paid on Thursday, January 11th. Shareholders of record on Thursday, November 9th will be paid a dividend of GBX 19 ($0.26) per share. This represents a dividend yield of 1.41%. The ex-dividend date is Thursday, November 9th.
In other GlaxoSmithKline news, insider Urs Rohner bought 473 shares of the company’s stock in a transaction dated Wednesday, October 25th. The shares were acquired at an average cost of GBX 1,518 ($20.43) per share, with a total value of £7,180.14 ($9,663.71). Also, insider Simon Dingemans bought 1,076 shares of the company’s stock in a transaction dated Thursday, October 12th. The shares were acquired at an average cost of GBX 1,527 ($20.55) per share, for a total transaction of £16,430.52 ($22,113.76). In the last 90 days, insiders have acquired 1,576 shares of company stock worth $2,400,376.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.